Cargando…

Microneedle-array patches loaded with dual mineralized protein/peptide particles for type 2 diabetes therapy

The delivery of therapeutic peptides for diabetes therapy is compromised by short half-lives of drugs with the consequent need for multiple daily injections that reduce patient compliance and increase treatment cost. In this study, we demonstrate a smart exendin-4 (Ex4) delivery device based on micr...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Wei, Tian, Rui, Xu, Can, Yung, Bryant C., Wang, Guohao, Liu, Yijing, Ni, Qianqian, Zhang, Fuwu, Zhou, Zijian, Wang, Jingjing, Niu, Gang, Ma, Ying, Fu, Liwu, Chen, Xiaoyuan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5701150/
https://www.ncbi.nlm.nih.gov/pubmed/29176623
http://dx.doi.org/10.1038/s41467-017-01764-1
Descripción
Sumario:The delivery of therapeutic peptides for diabetes therapy is compromised by short half-lives of drugs with the consequent need for multiple daily injections that reduce patient compliance and increase treatment cost. In this study, we demonstrate a smart exendin-4 (Ex4) delivery device based on microneedle (MN)-array patches integrated with dual mineralized particles separately containing Ex4 and glucose oxidase (GOx). The dual mineralized particle-based system can specifically release Ex4 while immobilizing GOx as a result of the differential response to the microenvironment induced by biological stimuli. In this manner, the system enables glucose-responsive and closed-loop release to significantly improve Ex4 therapeutic performance. Moreover, integration of mineralized particles can enhance the mechanical strength of alginate-based MN by crosslinking to facilitate skin penetration, thus supporting painless and non-invasive transdermal administration. We believe this smart glucose-responsive Ex4 delivery holds great promise for type 2 diabetes therapy by providing safe, long-term, and on-demand Ex4 therapy.